Topics

Companies Related to "Protein Coupled Bile Acid Receptor Pipeline Review 2019" [Most Relevant Company Matches] RSS

09:24 EST 22nd January 2020 | BioPortfolio

Here are the most relevant search results for "Protein Coupled Bile Acid Receptor Pipeline Review 2019" found in our extensive corporate database of over 50,000 company records.

Showing "Protein Coupled Bile Acid Receptor Pipeline Review 2019" Companies 1–25 of 2,500+

Relevant

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.


ConfometRx

ConfometRx is pioneering a platform of structure-based drug development tools that facilitate target validation, lead identification, and lead optimization for G protein coupled receptor (GPCR) targets. This platform includes biochemical and biophysical technologies for defining drug binding sites; the production of pure, functional GPCRs for high-resolution structure determination by crystallogra...

Receptos, Inc.

Receptos is a biopharmaceutical company developing best- and first-in-class G protein-coupled receptor (GPCR) therapeutic candidates through information-driven drug discovery, including GPCR structure determination. The company’s lead program is a best-in-class S1P1 small molecule, agonist candidate for autoimmune indications, including multiple scler...


Lundbeck Research USA, Inc.

Now that scientists have mapped the human genome, new opportunities exist for developing drugs that exclusively target specific receptors associated with the symptoms and causes of a disease.Receptor-specific drugs provide a new model in drug discovery that can improve the state-of-the-art treatment for many serious and common disorders. Lundbeck Research USA uses this discovery model to pursue n...

Azevan Pharmaceuticals, Inc.

Azevan Pharmaceuticals, Inc. (Azevan or the Company) is developing novel therapeutics for the treatment of disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. Azevan’s first series of clinical candidates selectively block the effects...

Arena Pharmaceuticals®

Arena is a biopharmaceutical company developing a broad pipeline of compounds that act on G protein-coupled receptors, or GPCRs. The company focuses on the discovery, development, and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory, and central nervous system diseases.

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Escient Pharmaceuticals

Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-...

REMD Biotherapeutics, Inc.

REMD Biotherapeutics is a privately held, clinical-stage biotechnology company focused on creating and developing innovative protein-based therapies to treat metabolic diseases and other serious illnesses. The Company was founded by two former Amgen research scientists and has facilities in Camarillo, California and Beijing China (Cosci-REMD Biotherapeutic...

Escient Pharmaceuticals, Inc.

Escient Pharmaceuticals is a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Focused on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-...

Unum Therapeutics Inc.

Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeut...

Trevena Inc.

Trevena, Inc. is a leader in the discovery and development of GPCR biased ligand drugs. Trevena combines a powerful and efficient drug discovery platform with extensive development experience to yield a rich linked portfolio of novel medicines. Trevena’s proprietary Advanced Biased Ligand Explorer, or ABLE™, platform includes customized assays, p...

Trevena, Inc.

Trevena, Inc. is a leader in the discovery and development of GPCR biased ligand drugs. Trevena combines a powerful and efficient drug discovery platform with extensive development experience to yield a rich linked portfolio of novel medicines. Trevena’s proprietary Advanced Biased Ligand Explorer, or ABLE™, platform includes customized assays, p...

Expert Opinion

The Expert Opinion series of review journals provides systematic and authoritative analysis to support every stage in the pharmaceutical pipeline. Our expertly crafted review articles enable the R&D community to access and track the key advances that lead to the creation of new drugs.

ENYO Pharma

ENYO Pharma is a privately held, clinical stage biopharmaceutical company incorporated in January 2014 and headquartered in Lyon, France. The Company’s most advanced compound, EYP001, is a small molecule (non-Bile Acid FXR agonist) therapeutic in Phase II clinical development for the treatment of Chronic Hepatitis B and NASH. EYP001 and the Company’s discovery programs are based on a pr...

Endocyte

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal healthy cells causing serious side effects. These side effects can be life-threatening which leads to suboptimal dosing. Receptor-targeted therapeutics can be more effective because they can be targete...

Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for delivery of a variety of drug payloads, including nucleic acid d...

BeneVia

BeneVia® is a healthy nutritional juice drink fortified with the essential vitamins and minerals and specialized protein & amino acid leucine sources for healthy aging. Clinical research has shown that the proprietary BeneVia® blend of these protein and nutrients is four times more effective than other protein sources for improving muscle function and energy levels for daily activity.

Aro Biotherapeutics Company

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for tissue specific targeting of therapeutics, including nucleic acid drugs for a diverse set of diseases. Fo...

Informa Healthcare - Expert Opinion series

The Expert Opinion series of review journals provides systematic and authoritative analysis to support every stage in the pharmaceutical pipeline. Our expertly crafted review articles enable the R&D community to access and track the key advances that lead to the creation of new drugs

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

Novasite Pharmaceuticals, Inc

Novasite is a drug discovery company using structure-function relationships in validated G protein coupled receptor targets to find better GPCR modulating drugs.Novasite began as a majority-owned subsidiary of Applied Molecular Evolution, Inc. (“AME”), which was acquired by Eli Lilly in 2004 for $400M. Novasite is the exclusive licensee of AME molecular evolution technology, which the Company ...

Ziarco

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-3893787, an H4 receptor antagonist that has completed a Phase 1 multiple ascending dose study. A second clinical-stage, programme targets inflammatory disorders by inhibiting cyto...

Target Discovery, Inc.

Target Discovery discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and management of disease. A growing body of scientific literature shows that protein isoforms correlate more precisely with disease state and patient-specific treatment response than current clinical biomarkers. Most protein isoforms (90%) are made by the body after the protein is produced (post-tra...


More From BioPortfolio on "Protein Coupled Bile Acid Receptor Pipeline Review 2019"

Quick Search

Corporate Database Quicklinks